Eric Palmer - Cigna Corp Chief Financial Officer, Executive Vice President
| CI Stock | USD 337.80 1.30 0.39% |
President
Mr. Eric P. Palmer is an Chief Financial Officer, Executive Vice President of the Company. He was with the Company since 1998. He served as the Company Deputy Chief Financial Officer from February 2017 through June 15, 2017 Senior Vice President, Chief Business Financial Officer from November 2015 through February 2017 Vice President, Business Financial Officer, Health Care from April 2012 through November 2015 and Vice President, Business Financial Officer, U.S. Commercial Markets from June 2010 through April 2012. Between 1998 when he joined Cigna and June 2010, Mr. Palmer held various roles with increasing responsibility in areas including pricing, reserves, underwriting and financial planning and analysis. Mr. Palmer is a Fellow of the Society of Actuaries and a Member of the American Academy of Actuaries. since 2022.
| Age | 48 |
| Tenure | 2 years |
| Address | 900 Cottage Grove Road, Bloomfield, CT, United States, 06002 |
| Phone | 860 226 6000 |
| Web | https://www.cigna.com |
Cigna Corp Management Efficiency
The company has Return on Asset (ROA) of 0.028 % which means that for every $100 of assets, it generated a profit of $0.028. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0761 %, which means that it produced $0.0761 on every 100 dollars invested by current stockholders. Cigna Corp's management efficiency ratios could be used to measure how well Cigna Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Cigna Corp's Return On Tangible Assets are increasing as compared to previous years. The Cigna Corp's current Return On Capital Employed is estimated to increase to 0.09, while Return On Equity is projected to decrease to 0.10. As of now, Cigna Corp's Intangible Assets are increasing as compared to previous years. The Cigna Corp's current Return On Tangible Assets is estimated to increase to 0.07, while Total Assets are projected to decrease to under 89.1 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Joshua Flum | CVS Health Corp | 50 | |
| Jesse Hunter | Centene Corp | 44 | |
| Dawn Maroney | Alignment Healthcare LLC | 56 | |
| Jonathan Roberts | CVS Health Corp | 65 | |
| James Woys | Molina Healthcare | 65 | |
| Eva Boratto | CVS Health Corp | 53 | |
| Christopher Hunter | Humana Inc | 52 | |
| William Fleming | Humana Inc | 53 | |
| Scott Towers | Elevance Health | N/A | |
| Katie Casso | Centene Corp | 42 | |
| MPP MD | CVS Health Corp | N/A | |
| Christopher Koster | Centene Corp | 59 | |
| Prem Shah | CVS Health Corp | 41 | |
| John III | Humana Inc | N/A | |
| H Sanders | Centene Corp | N/A | |
| Keith Williamson | Centene Corp | 66 | |
| John Rex | UnitedHealth Group Incorporated | 62 | |
| Charlotte LeBlanc | Alignment Healthcare LLC | N/A | |
| Alan Wheatley | Humana Inc | 51 | |
| John Kao | Alignment Healthcare LLC | 62 | |
| Lisa Bisaccia | CVS Health Corp | 62 | |
Management Performance
| Return On Equity | 0.0761 | ||||
| Return On Asset | 0.028 |
Cigna Corp Leadership Team
Elected by the shareholders, the Cigna Corp's board of directors comprises two types of representatives: Cigna Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cigna. The board's role is to monitor Cigna Corp's management team and ensure that shareholders' interests are well served. Cigna Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cigna Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arjan Toor, Chief Operations | ||
| Nicole Jones, Executive Vice President, General Counsel | ||
| Matthew Manders, President of U.S. Commercial Markets and Global Health Care Operations | ||
| Donna Zarcone, Independent Director | ||
| Noelle Eder, Executive Vice President, Global Chief Information Officer | ||
| Eric Palmer, Chief Financial Officer, Executive Vice President | ||
| Dean Mirabella, President Markets | ||
| John Webb, President - Health Care | ||
| Cynthia Ryan, Chief Human Resource Officer | ||
| Alexis Jones, Investor Principal | ||
| Mark Boxer, Executive Vice President, Chief Information Officer | ||
| Neesha Hathi, Independent Director | ||
| Nicole JD, Chief VP | ||
| Adam PharmD, President Services | ||
| Jason Sadler, President of International Markets | ||
| Eric Foss, Independent Director | ||
| Timothy Wentworth, Chief Executive Officer - Evernorth | ||
| Isaiah Harris, Independent Chairman of the Board | ||
| John Murabito, Executive Vice President - Human Resources, Chief Administrative Officer | ||
| Christopher MBA, President Businesses | ||
| Roman Martinez, Independent Director | ||
| William DeLaney, Independent Director | ||
| Kristen Lauria, Executive Vice President, Chief Marketing Officer | ||
| Everett Neville, Executive Vice President, Strategy, Corporate Development and Solutions | ||
| Ralph Giacobbe, Senior Relations | ||
| Phil Austin, Head Markets | ||
| Paul Sanford, Executive Vice President - Operations | ||
| John Partridge, Independent Director | ||
| Jamie Kates, Chief Officer | ||
| Mark McClellan, Independent Director | ||
| Kathleen Mazzarella, Independent Director | ||
| Mary CPA, Senior Officer | ||
| MICHAEL TRIPLETT, President - U.S. Commercial | ||
| Steven Miller, Executive Vice President Chief Clinical Officer | ||
| Elder Granger, Independent Director | ||
| Kimberly Ross, Independent Director | ||
| Mary Picerno, Chief Officer | ||
| Brian CFA, CFO VP | ||
| Eric Wiseman, Lead Independent Director | ||
| Brian Evanko, Chief Financial Officer, Executive Vice President | ||
| Matt Perlberg, Pharmacy President | ||
| Kari Stevens, Chief VP | ||
| David Cordani, CEO and President Director and Member of Executive Committee | ||
| Terese CPA, Senior Officer | ||
| William Roper, Independent Director | ||
| George Kurian, Independent Director | ||
| Charles Berg, President - U.S. Government Business |
Cigna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cigna Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0761 | ||||
| Return On Asset | 0.028 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 120.51 B | ||||
| Shares Outstanding | 278.15 M | ||||
| Shares Owned By Insiders | 1.59 % | ||||
| Shares Owned By Institutions | 89.54 % | ||||
| Number Of Shares Shorted | 3.58 M | ||||
| Price To Earning | 13.93 X |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cigna Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more detail on how to invest in Cigna Stock please use our How to Invest in Cigna Corp guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cigna Corp. If investors know Cigna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cigna Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.45) | Dividend Share 5.43 | Earnings Share 10.54 | Revenue Per Share 808.024 | Quarterly Revenue Growth 0.28 |
The market value of Cigna Corp is measured differently than its book value, which is the value of Cigna that is recorded on the company's balance sheet. Investors also form their own opinion of Cigna Corp's value that differs from its market value or its book value, called intrinsic value, which is Cigna Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cigna Corp's market value can be influenced by many factors that don't directly affect Cigna Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cigna Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cigna Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cigna Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.